HAEMONETICS CORP's ticker is HAE and the CUSIP is 405024100. A total of 268 filers reported holding HAEMONETICS CORP in Q3 2020. The put-call ratio across all filers is 0.64 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $354,647 | +5.7% | 3,959 | +0.5% | 0.01% | +9.1% |
| Q2 2023 | $335,367 | +2.9% | 3,939 | 0.0% | 0.01% | 0.0% |
| Q1 2023 | $325,952 | +106073.3% | 3,939 | +0.8% | 0.01% | 0.0% |
| Q4 2022 | $307 | -99.9% | 3,909 | 0.0% | 0.01% | 0.0% |
| Q3 2022 | $290,000 | +13.7% | 3,909 | -0.4% | 0.01% | +22.2% |
| Q2 2022 | $255,000 | +3.7% | 3,926 | +1.0% | 0.01% | +12.5% |
| Q1 2022 | $246,000 | +18.3% | 3,888 | -0.9% | 0.01% | +33.3% |
| Q4 2021 | $208,000 | -24.9% | 3,923 | -0.0% | 0.01% | -45.5% |
| Q3 2021 | $277,000 | +5.3% | 3,924 | -0.8% | 0.01% | 0.0% |
| Q2 2021 | $263,000 | -64.1% | 3,955 | -40.1% | 0.01% | -65.6% |
| Q1 2021 | $732,000 | -6.9% | 6,600 | -0.3% | 0.03% | -11.1% |
| Q4 2020 | $786,000 | +228.9% | 6,617 | +141.9% | 0.04% | +200.0% |
| Q3 2020 | $239,000 | +305.1% | 2,735 | +363.6% | 0.01% | +200.0% |
| Q4 2018 | $59,000 | -35.2% | 590 | -25.8% | 0.00% | -20.0% |
| Q3 2018 | $91,000 | – | 795 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Nitorum Capital, L.P. | 413,122 | $16,608,000 | 4.78% |
| Altalis Capital Management LLC | 88,055 | $3,540,000 | 3.97% |
| RUTABAGA CAPITAL MANAGEMENT LLC/MA | 513,619 | $20,647,000 | 3.54% |
| Black Creek Investment Management Inc. | 1,118,613 | $44,968,000 | 3.46% |
| HealthCor Management, L.P. | 1,150,000 | $46,230,000 | 2.61% |
| Van Berkom & Associates Inc. | 1,136,971 | $45,706,000 | 1.83% |
| AMERICAN CAPITAL MANAGEMENT INC | 567,896 | $22,829,000 | 1.77% |
| FULLER & THALER ASSET MANAGEMENT, INC. | 2,062,539 | $82,914,000 | 1.25% |
| Legato Capital Management LLC | 1,336 | $53,707,000 | 0.97% |
| HEARTLAND ADVISORS INC | 351,314 | $14,123,000 | 0.78% |